



March 26, 2018

## **TG Therapeutics, Inc. to Present at the Needham 17th Annual Healthcare Conference**

### **Presentation scheduled for Wednesday, March 28, 2018 at 4:00pm ET**

NEW YORK, March 26, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced that Michael S. Weiss, the Company's Executive Chairman and Chief Executive Officer, will present at the Needham 17<sup>th</sup> Annual Healthcare Conference, being held at the Westin Grand Central Hotel, in New York City. The presentation is scheduled to take place on Wednesday, March 28, 2018 at 4:00pm ET.

A live webcast of this presentation will be available on the Events page, located within the Investors & Media section of the Company's website at [www.tgtherapeutics.com](http://www.tgtherapeutics.com).

### **ABOUT TG THERAPEUTICS, INC.**

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. Ublituximab (TG-1101) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing umbralisib (TGR-1202), an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both ublituximab and umbralisib, or the combination of which is referred to as "U2", are in Phase 3 clinical development for patients with hematologic malignancies, with ublituximab also in Phase 3 clinical development for Multiple Sclerosis. Additionally, the Company has recently brought its anti-PD-L1 monoclonal antibody into Phase 1 development and aims to bring additional pipeline assets into the clinic in the future. TG Therapeutics is headquartered in New York City.

### **CONTACT:**

Jenna Bosco  
SVP, Corporate Communications  
TG Therapeutics, Inc.  
Telephone: 212.554.4351  
Email: [ir@tgtxinc.com](mailto:ir@tgtxinc.com)

 [Primary Logo](#)

Source: TG Therapeutics, Inc.

News Provided by Acquire Media